SCA
CODX

Snowden Capital Advisors’s Co-Diagnostics CODX Stock Holding History

Snowden Capital Advisors’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-27
Closed -$7K – 1241
2021
Q4 		$7K Buy
+27
New +$7.08K ﹤0.01% 1598

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ARC
Advisor Resource Council Dallas, Texas $355M AUM 30.05% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return

Snowden Capital Advisors's CODX Position: Q1 2022 in Review

Snowden Capital Advisors sold out of Co-Diagnostics (CODX) in Q1 2022, closing a stake of 27 shares — an estimated $7K sold.

Snowden Capital Advisors first reported a position in CODX in Q4 2021 and held it in 1 quarter. The position peaked at $7K in Q4 2021. 82 funds tracked by Wall St. Rank hold CODX as of Q1 2022.

  • Snowden Capital Advisors reported no remaining Co-Diagnostics position as of Q1 2022 after selling out during the quarter.
  • Snowden Capital Advisors sold 27 Co-Diagnostics shares in Q1 2022, an estimated $7K.
  • Snowden Capital Advisors first reported a position in Co-Diagnostics in Q4 2021 and held it in 1 quarter.
  • Snowden Capital Advisors's Co-Diagnostics position peaked at $7K in Q4 2021.
  • 82 funds tracked by Wall St. Rank held Co-Diagnostics as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.